Long ago, the colors of fabrics were more than just fashion statements. They were a nonverbal form of communication that ...

The Hebrew Language Academy has the final word on what is and what isn't correct in Hebrew vocabulary, grammar, writing, ...

Despite its unique ability to block sodium-glucose linked transporter 2 (SGLT2) in the kidneys and SGLT1 in the intestines, Lexicon’s Zynquista (sotagliflozin) has had difficulty negotiating ...

(RTTNews) - Lexicon Pharmaceuticals Inc. (LXRX) announced that the U.S. Food and Drug Administration's Advisory Committee voted against the company's New Drug Application (NDA) for Zynquista ...

Oct 31 (Reuters) - Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' (LXRX.O), opens new tab add-on treatment to insulin ...

What do scriptural accounts of monstrous beings like Leviathan and Behemoth tell us about our experience of the sacred? When I started reading the Bible as a teenager, I was shocked to read the ...

Senior Lecturer in Biblical and Religious Studies, University of Sheffield But beneath the use of Jezebel’s name as a way to paint powerful women as promiscuous lies something even more sinister ...

María Pilar Agustín-Llach [Opens in a new window] and The present study delves into the structure and lexical organization of L1 and L2 mental lexicons. Indirect access to the mental lexicon is ...

Lexicon (LXRX) announced that patient screening has been completed in the Phase 2b PROGRESS clinical trial evaluating the company’s AAK1 inhibitor, LX9211, for the treatment of Diabetic ...

The most common reason: a lack of interest in politics and elections. In a world where secular values often clash with biblical truth, it's crucial that Christians understand their responsibility to ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Lexicon Pharmaceuticals (LXRX – Research Report), with a price target of $10.00. The company’s shares ...

The deal is a boost to Lexicon, because the company was unlikely to try to sell Inpefa outside of the U.S. on its own, according to Jefferies’ Tsai. Meanwhile, the drug fits into plans by Viatris to ...